GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...
Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.
Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00.
(All Report Archive)
Is David Dodd on to his Next Billion Dollar Payday for Shareholders?
Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors.
GeoVax (GOVX) Completes Patient...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
